Latest News | Biocon Biologics Facility Gets EU GMP Certification for Bevacizumab

New Delhi, Apr 28 (PTI) Biotechnology major Biocon on Friday said the Bengaluru-based plant of Biocon Biologics has received EU GMP approval for a biosimilar product.

Also Read | Job Openings in India: Hospitality Sector Sees 60% Rise in Job Postings, Delhi-NCR Emerging As Top City for Such Jobs.

Biocon Biologics' facility has received a certificate of GMP compliance for Bevacizumab from the representative European inspection authority -- Health Products Regulatory Authority (HPRA), Ireland.

Bevacizumab is indicated for the treatment of various types of cancers and a specific eye disease.

Also Read | Relief From Irritating Calls! TRAI Introduces New Changes Regarding Spam Calls and SMS From May 1.

"This approval reflects Biocon Biologics compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients in the EU," a company spokesperson said in a statement.

This (B3) facility, which is one of India's largest monoclonal antibodies (mAbs) manufacturing facilities, had received the EU GMP Certification for manufacturing biosimilar Trastuzumab last year, the spokesperson said.

Biocon Biologics is a subsidiary of Biocon Ltd.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)